Irinotecan Hydrochloride Patent Expiration
Irinotecan Hydrochloride is used for treating metastatic colorectal cancer in combination with 5-fluorouracil, leucovorin, and irinotecan. It was first introduced by Pfizer Inc
Irinotecan Hydrochloride Patents
Given below is the list of patents protecting Irinotecan Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Camptosar | US6403569 | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
Apr 28, 2020
(Expired) | Pfizer Inc |
| Camptosar |
US6403569 (Pediatric) | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
Oct 28, 2020
(Expired) | Pfizer Inc |
| Camptosar | US6794370 | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
May 01, 2020
(Expired) | Pfizer Inc |
| Camptosar |
US6794370 (Pediatric) | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
Nov 01, 2020
(Expired) | Pfizer Inc |
| Onivyde | US10456360 | Stabilizing camptothecin pharmaceutical compositions | Oct 15, 2036 | Ipsen |
| Onivyde | US10722508 | Liposomes useful for drug delivery | May 02, 2025 | Ipsen |
| Onivyde | US10980795 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | Jun 12, 2033 | Ipsen |
| Onivyde | US10993914 | Stabilizing camptothecin pharmaceutical compositions | Oct 15, 2036 | Ipsen |
| Onivyde | US11344552 | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin | Aug 19, 2036 | Ipsen |
| Onivyde | US11369597 | Methods for treating pancreatic cancer using combination therapies | Jun 12, 2033 | Ipsen |
| Onivyde | US8147867 | Liposomes useful for drug delivery | Aug 29, 2028 | Ipsen |
| Onivyde | US8329213 | Liposomes useful for drug delivery | Jan 06, 2027 | Ipsen |
| Onivyde | US8703181 | Liposomes useful for drug delivery | May 02, 2025 | Ipsen |
| Onivyde | US8992970 | Liposomes useful for drug delivery | May 02, 2025 | Ipsen |
| Onivyde | US9339497 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | Jun 12, 2033 | Ipsen |
| Onivyde | US9364473 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | Jun 12, 2033 | Ipsen |
| Onivyde | US9452162 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | Jun 12, 2033 | Ipsen |
| Onivyde | US9492442 | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | Jun 12, 2033 | Ipsen |
| Onivyde | US9717724 | Methods for treating pancreatic cancer using combination therapies | Jun 12, 2033 | Ipsen |
| Onivyde | US9724303 | Liposomes useful for drug delivery | May 02, 2025 | Ipsen |
| Onivyde | US9730891 | Liposomes useful for drug delivery | May 02, 2025 | Ipsen |
| Onivyde | US9782349 | Liposomes useful for drug delivery | May 02, 2025 | Ipsen |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Irinotecan Hydrochloride Generics
Several generic applications have been filed for Irinotecan Hydrochloride. The first generic version for Irinotecan Hydrochloride was by Cipla Ltd and was approved on Feb 20, 2008. And the latest generic version is by Eugia Pharma Specialities Ltd and was approved on Apr 11, 2022.
Given below is the list of companies who have filed for Irinotecan Hydrochloride generic.
1. EMCURE PHARMS LTD
Emcure Pharmaceuticals Ltd has filed for 2 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by Emcure Pharms Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG/2ML (20MG/ML) | injectable | Discontinued | INJECTION | N/A | Feb 14, 2012 |
| 100MG/5ML (20MG/ML) | injectable | Discontinued | INJECTION | N/A | Feb 14, 2012 |
2. CIPLA LTD
Cipla Ltd has filed for 2 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by Cipla Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG/2ML (20MG/ML) | injectable | Discontinued | INJECTION | N/A | Feb 20, 2008 |
| 100MG/5ML (20MG/ML) | injectable | Discontinued | INJECTION | N/A | Feb 20, 2008 |
3. HIKMA FARMACEUTICA
Hikma Farmaceutica (portugal) Sa has filed for 2 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by Hikma Farmaceutica.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG/2ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Dec 20, 2010 |
| 100MG/5ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Dec 20, 2010 |
4. INTAS PHARMS USA
Intas Pharmaceuticals Usa has filed for 2 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by Intas Pharms Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG/5ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Aug 31, 2017 |
| 40MG/2ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Aug 31, 2017 |
5. EUGIA PHARMA
Eugia Pharma Specialities Ltd has filed for 4 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by Eugia Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG/2ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Nov 2, 2020 |
| 100MG/5ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Nov 2, 2020 |
| 300MG/15ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Nov 2, 2020 |
| 500MG/25ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Apr 11, 2022 |
6. HISUN PHARM HANGZHOU
Hisun Pharmaceutical (hangzhou) Co Ltd has filed for 2 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by Hisun Pharm Hangzhou.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG/5ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Jan 28, 2009 |
| 40MG/2ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Jan 28, 2009 |
7. PLIVA LACHEMA
Pliva Lachema As has filed for 2 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by Pliva Lachema.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG/5ML (20MG/ML) | injectable | Discontinued | INJECTION | N/A | Oct 31, 2008 |
| 40MG/2ML (20MG/ML) | injectable | Discontinued | INJECTION | N/A | Oct 31, 2008 |
8. TEVA PHARMS USA
Teva Pharmaceuticals Usa has filed for 3 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG/5ML (20MG/ML) | injectable | Discontinued | INJECTION | N/A | Feb 27, 2008 |
| 40MG/2ML (20MG/ML) | injectable | Discontinued | INJECTION | N/A | Feb 27, 2008 |
| 500MG/25ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Nov 26, 2008 |
9. QILU PHARM HAINAN
Qilu Pharmaceutical Hainan Co Ltd has filed for 3 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by Qilu Pharm Hainan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG/5ML (20MG/ML) | injectable | Prescription | INJECTION | AP | May 3, 2016 |
| 40MG/2ML (20MG/ML) | injectable | Prescription | INJECTION | AP | May 3, 2016 |
| 300MG/15ML (20MG/ML) | injectable | Prescription | INJECTION | AP | May 3, 2016 |
10. GLAND PHARMA LTD
Gland Pharma Ltd has filed for 2 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by Gland Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG/2ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Nov 18, 2019 |
| 100MG/5ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Nov 18, 2019 |
11. HENGRUI PHARMA
Jiangsu Hengrui Pharmaceuticals Co Ltd has filed for 2 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by Hengrui Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG/2ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Dec 16, 2011 |
| 100MG/5ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Dec 16, 2011 |
12. ZENNOVA
Zennova Pharmaceuticals Chengdu Co Ltd has filed for 2 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by Zennova.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG/2ML (20MG/ML) | injectable | Prescription | INJECTION | AP | May 13, 2011 |
| 100MG/5ML (20MG/ML) | injectable | Prescription | INJECTION | AP | May 13, 2011 |
13. WEST-WARD PHARMS INT
West-ward Pharmaceuticals International Ltd has filed for 2 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by West-ward Pharms Int.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG/2ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Dec 24, 2008 |
| 100MG/5ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Dec 24, 2008 |
14. ACCORD HLTHCARE
Accord Healthcare Inc has filed for 2 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG/5ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Nov 21, 2008 |
| 40MG/2ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Nov 21, 2008 |
15. CHARTWELL RX
Chartwell Rx Sciences Llc has filed for 2 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by Chartwell Rx.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG/2ML (20MG/ML) | injectable | Discontinued | INJECTION | N/A | Apr 15, 2010 |
| 100MG/5ML (20MG/ML) | injectable | Discontinued | INJECTION | N/A | Apr 15, 2010 |
16. SANDOZ
Sandoz Inc has filed for 2 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by Sandoz.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG/2ML (20MG/ML) | injectable | Discontinued | INJECTION | N/A | Nov 12, 2009 |
| 100MG/5ML (20MG/ML) | injectable | Discontinued | INJECTION | N/A | Nov 12, 2009 |
17. ACTAVIS TOTOWA
Actavis Totowa Llc has filed for 3 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by Actavis Totowa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG/2ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Feb 27, 2008 |
| 100MG/5ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Feb 27, 2008 |
| 500MG/25ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Nov 18, 2015 |
18. FRESENIUS KABI USA
Fresenius Kabi Usa Llc has filed for 2 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by Fresenius Kabi Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG/2ML (20MG/ML) | injectable | Discontinued | INJECTION | N/A | Feb 27, 2008 |
| 100MG/5ML (20MG/ML) | injectable | Discontinued | INJECTION | N/A | Feb 27, 2008 |
19. HOSPIRA
Hospira Inc has filed for 3 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by Hospira.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MG/5ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Feb 27, 2008 |
| 40MG/2ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Feb 27, 2008 |
| 500MG/25ML (20MG/ML)
(reference standard) | injectable | Prescription | INJECTION | AP | Feb 27, 2008 |
20. SHILPA
Shilpa Medicare Ltd has filed for 3 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by Shilpa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG/2ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Dec 28, 2018 |
| 100MG/5ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Dec 28, 2018 |
| 300MG/15ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Aug 16, 2019 |
21. SUN PHARMA GLOBAL
Sun Pharma Global Inc has filed for 2 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by Sun Pharma Global.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG/2ML (20MG/ML) | injectable | Discontinued | INJECTION | N/A | Apr 21, 2008 |
| 100MG/5ML (20MG/ML) | injectable | Discontinued | INJECTION | N/A | Apr 21, 2008 |
22. EPIC PHARMA LLC
Epic Pharma Llc has filed for 2 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by Epic Pharma Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG/2ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Sep 16, 2009 |
| 100MG/5ML (20MG/ML) | injectable | Prescription | INJECTION | AP | Sep 16, 2009 |
23. NOVAST LABS
Novast Laboratories Ltd has filed for 2 different strengths of generic version for Irinotecan Hydrochloride. Given below are the details of the strengths of this generic introduced by Novast Labs.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG/2ML (20MG/ML) | injectable | Prescription | INJECTION | AP | May 26, 2017 |
| 100MG/5ML (20MG/ML) | injectable | Prescription | INJECTION | AP | May 26, 2017 |